PBE
Invesco Biotechnology & Genome ETF
Price Chart
Latest Quote
$100.00
+0.80 (+0.80%)
Current Price
| Previous Close | $99.21 |
| Open | $99.04 |
| Day High | $100.00 |
| Day Low | $98.83 |
| Volume | 2,328 |
Fund Information
| Quarterly Dividend / Yield | N/A / 1.37% |
| Shares Outstanding | 4.55M |
| Net Assets | $423.52M |
| Expense Ratio | 0.59% |
| Category | Health |
| Fund Family | Invesco |
| Net Asset Value | $99.28 |
| Premium/Discount | 0.73% |
| Quarterly Dividend Yield | 1.37% |
| P/E Ratio | 27.50 |
| Exchange | PCX |
đ ETF Analysis
Company Data
| Book/sh | $75.35 |
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 1.34 |
Analyst Data
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| SMA200 | $nan |
| RSI | 63.45 |
| ATR | nan |
| Rel Volume | 0.43 |
Performance History
| Week | nan% |
| Month | nan% |
| Quarter | nan% |
| 6 Months | nan% |
| YTD | nan% |
| Year | nan% |
| 3 Years | nan% |
| 5 Years | nan% |
| 10 Years | nan% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $nan | 5,487 |
| 2026-10-26 | $99.21 | 20,100 |
| 2026-10-23 | $98.72 | 7,700 |
| 2026-10-22 | $99.38 | 9,900 |
| 2026-10-21 | $99.56 | 13,300 |
| 2026-10-20 | $99.22 | 12,100 |
| 2026-10-19 | $96.71 | 43,000 |
| 2026-10-16 | $96.08 | 11,200 |
| 2026-10-15 | $98.65 | 29,900 |
| 2026-10-14 | $96.72 | 5,900 |
| 2026-10-13 | $94.94 | 3,500 |
| 2026-10-12 | $96.44 | 3,300 |
| 2026-10-09 | $96.90 | 2,900 |
| 2026-10-08 | $94.25 | 8,800 |
| 2026-10-07 | $94.83 | 8,700 |
| 2026-10-06 | $94.70 | 8,100 |
| 2026-10-05 | $97.04 | 21,100 |
| 2026-10-02 | $95.07 | 18,100 |
| 2026-10-01 | $95.10 | 13,200 |
| 2026-09-30 | $97.29 | 11,700 |
| 2026-09-29 | $97.16 | 19,900 |
| 2026-09-28 | $97.29 | 12,100 |
About Invesco Biotechnology & Genome ETF
The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
đ° Latest News
No news articles available at the moment. Check back later for updates on PBE.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.